Sino Biopharmaceutical Limited Overview
Pro stress-test →Sino Biopharmaceutical Limited is a research and development pharmaceutical conglomerate in China operating through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company develops and manufactures a diverse portfolio of oncology, liver disease, and respiratory system medicines, positioning itself as an innovation-driven player in the Chinese pharmaceutical market.
Strategic Profile
Pro stress-test →The company offers a comprehensive oncology portfolio including anlotinib, penpulimab, and multiple targeted therapies with branded products like Focus V, Annike, and Yilishu. This diversified therapeutic approach combined with both Western and modernized Chinese medicine capabilities provides competitive differentiation in a large and growing market.
Competitive Landscape
Pro stress-test →Sino Biopharmaceutical competes in China's dynamic pharmaceutical market against both domestic players and multinational pharma companies. The company differentiates through its focus on oncology innovation, modernized Chinese medicines, and a diversified therapeutic portfolio. Key competitive advantages include manufacturing scale, distribution networks, and R&D capabilities in high-growth therapeutic areas.
Industry Context
Sino Biopharmaceutical Limited operates in Pharmaceuticals & Biotechnology.
Key facts
Headquarters: Hong Kong, China · Revenue: 19.26B HKD (half-year 2025)